Teva Pharmaceutical Industries (NYSE:TEVA) Trading Up 4.3% - Should You Buy?

Key Points

• Teva Pharmaceutical Industries' stock rose 4.3%, trading at $20.00 after reaching a high of $19.94, but experienced a significant decline in trading volume compared to the average.
• Wall Street analysts have a consensus rating of "Buy" on Teva, with target prices ranging from $24.00 to $26.00 indicating potential growth.
• Insider selling activity was observed, with notable transactions from company insiders reducing their ownership by significant percentages.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report)'s share price was up 4.3% on Tuesday . The stock traded as high as $19.94 and last traded at $20.00. Approximately 5,452,116 shares traded hands during trading, a decline of 54% from the average daily volume of 11,857,882 shares. The stock had previously closed at $19.18.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on TEVA shares. Wall Street Zen upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. The Goldman Sachs Group started coverage on Teva Pharmaceutical Industries in a report on Friday, June 6th. They set a "buy" rating and a $24.00 target price on the stock. Finally, UBS Group boosted their target price on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock a "buy" rating in a report on Wednesday, September 24th. Two investment analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $25.14.

Teva Pharmaceutical Industries Trading Up 6.3%

The company's 50 day simple moving average is $17.83 and its 200 day simple moving average is $16.72. The firm has a market cap of $23.38 billion, a price-to-earnings ratio of -127.03, a P/E/G ratio of 1.07 and a beta of 0.72. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.06 and a quick ratio of 0.77.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its earnings results on Wednesday, July 30th. The company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.64 by $0.02. The firm had revenue of $4.18 billion for the quarter, compared to analyst estimates of $4.34 billion. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.Teva Pharmaceutical Industries's revenue for the quarter was up .3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.61 earnings per share. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. As a group, research analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Placid Jover sold 6,053 shares of the firm's stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $91,763.48. Following the completion of the sale, the insider owned 6,774 shares in the company, valued at $102,693.84. This trade represents a 47.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Eric A. Hughes sold 52,742 shares of the firm's stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $15.16, for a total transaction of $799,568.72. The disclosure for this sale can be found here. 0.55% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

A number of hedge funds and other institutional investors have recently modified their holdings of TEVA. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its stake in Teva Pharmaceutical Industries by 0.5% in the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 118,209 shares of the company's stock valued at $1,981,000 after buying an additional 615 shares during the last quarter. US Bancorp DE grew its stake in Teva Pharmaceutical Industries by 6.5% in the 1st quarter. US Bancorp DE now owns 10,812 shares of the company's stock valued at $166,000 after buying an additional 656 shares during the last quarter. MAI Capital Management grew its stake in Teva Pharmaceutical Industries by 26.8% in the 2nd quarter. MAI Capital Management now owns 3,293 shares of the company's stock valued at $55,000 after buying an additional 697 shares during the last quarter. Wedbush Securities Inc. grew its stake in Teva Pharmaceutical Industries by 3.3% in the 2nd quarter. Wedbush Securities Inc. now owns 21,995 shares of the company's stock valued at $369,000 after buying an additional 700 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in Teva Pharmaceutical Industries by 15.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,474 shares of the company's stock worth $92,000 after purchasing an additional 715 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.